Heinrich Stefan, Tripke Verena, Huber Tobias, Siegel Ekkehard, Dennebaum Martin, Staib Ludger, Wörns Marcus-Alexander, Oberholzer Katja, Mittler Jens, Lang Hauke
Allgemein‑, Viszeral- und Transplantationschirurgie, Universitätsmedizin Mainz, Langenbeckstraße 1, 55131, Mainz, Deutschland.
Institut für med. Mikrobiologie und Hygiene, Universitätsmedizin Mainz, Mainz, Deutschland.
Chirurg. 2020 Nov;91(11):943-954. doi: 10.1007/s00104-020-01157-z.
Echinococcosis is a rare parasitosis in Germany for which the World Health Organization recommends stage-specific treatment strategies.
The aim of this study was to analyze the treatment results of patients with hepatic echinococcosis at a German center of excellence for liver surgery.
Patients who underwent surgery for hepatic echinococcosis between 2009 and 2018 at the University Hospital of Mainz (UMM) were included in this follow-up examination. The investigation included a magnetic resonance imaging (MRI) of the abdomen, documentation of the quality of life (QoL), serological and laboratory parameters. In addition, an online survey was performed among surgeons from Middle Rhein and gastroenterologists from Rhineland-Palatinate.
At the UMM 25 surgical interventions were performed for hepatic echinococcosis: 9 for cystic (CE) and 16 for alveolar echinococcosis (AE). The majority of the interventions were major liver resections with additional vascular and biliary procedures. The 90-day mortality was 0%, and 4 grade 3a and 1 grade 4b complications occurred. In contrast to AE 75% of the postoperative serological results of patients with CE remained positive for more than 1 year postoperatively. Most participants in the survey knew the imaging characteristics and treatment options of AE and CE; however, many participants were unaware of the cost of the treatment.
From the perspective of surgeons, hepatic echinococcosis is a challenge, which however can be curatively treated with a low morbidity despite advanced disease in many patients. Due to the low incidence of the disease, the state of knowledge about AE and CE is limited among physicians.
棘球蚴病在德国是一种罕见的寄生虫病,世界卫生组织针对该病推荐了分阶段的治疗策略。
本研究旨在分析德国一家肝脏手术卓越中心的肝棘球蚴病患者的治疗结果。
纳入2009年至2018年在美因茨大学医院(UMM)接受肝棘球蚴病手术的患者进行本次随访检查。调查包括腹部磁共振成像(MRI)、生活质量(QoL)记录、血清学和实验室参数。此外,还对中莱茵地区的外科医生和莱茵兰 - 普法尔茨州的胃肠病学家进行了在线调查。
在UMM,共进行了25例肝棘球蚴病手术干预:9例为囊性(CE),16例为泡型棘球蚴病(AE)。大多数干预措施是大型肝切除术及额外的血管和胆道手术。90天死亡率为0%,发生了4例3a级和1例4b级并发症。与AE不同,CE患者术后75%的血清学结果在术后1年以上仍为阳性。大多数调查参与者了解AE和CE的影像学特征及治疗选择;然而,许多参与者不知道治疗费用。
从外科医生的角度来看,肝棘球蚴病是一项挑战,不过尽管许多患者病情已进展,但仍可通过低发病率的方式实现治愈性治疗。由于该病发病率低,医生对AE和CE的了解程度有限。